Pelican: MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Study Details
Study Description
Brief Summary
This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic Melanoma patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. This study will consist of two arms where the dose will be increased independently until the maximum tolerated dose (MTD) / maximum feasible dose (MFD) is reached.
Arm 1 - Low-dose cyclophosphamide, followed by an Ad-MAGEA3 intramuscular (IM) prime, followed by intravenous (IV) administration of MG1-MAGEA3 and IV pembrolizumab.
Arm 2 - Ad-MAGEA3 IM injection as a prime, followed by IV administration of MG1-MAGEA3, followed by intratumoral (IT) injection of MG1-MAGEA3 into tumors and IV pembrolizumab.
In the Phase 1b Expansion for each arm, additional patients will be enrolled at the MTD/MDF as determined in Phase 1 in order to more thoroughly explore immune response, pharmacokinetics/dynamics, and safety for Malignant Melanoma patients who have failed standard therapies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm 1: Intravenous Dosing Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort. |
Drug: Ad-MAGEA3
Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Drug: MG1-MAGEA3
MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Drug: Pembrolizumab
monoclonal antibody; checkpoint inhibitor of PD1
Other Names:
Drug: Cyclophosphamide
low-dose chemotherapy
|
| Experimental: Arm 2: Intravenous followed by Intratumoral Dosing A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6). |
Drug: Ad-MAGEA3
Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Drug: MG1-MAGEA3
MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Drug: Pembrolizumab
monoclonal antibody; checkpoint inhibitor of PD1
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Safety of Ad/MG1-MAGEA3 administration in Melanoma or Squamous Cell Skin Carcinoma [6 months]
Safety will be determined by assessing the severity and frequency of treatment emergent Adverse Events and clinical laboratory toxicity using NCI CTCAE v 5.0
- Determine the maximum tolerated dose (MTD)/ maximum feasible dose (MFD) of Ad/MG1-MAGEA3 in Melanoma or Squamous Cell Skin Carcinoma [5 weeks]
MTD/MFD of Ad/MG1-MAGEA3 administered by IV infusion alone and IV infusion followed by direct injection of tumor (IT injection) in Melanoma or Squamous Cell Skin Carcinoma
Secondary Outcome Measures
- Evaluate Overall Response [2 years]
Determine the overall response rate (Partial Response (PR) + Complete Response (CR))
- Evaluate Disease Control [2 years]
Determine Disease Control Rate (PR+CR+Stable Disease (SD))
- Evaluate PFS [2 years]
Progression free survival in months
- Evaluate Duration of Response, if any [2 years]
Duration of Response (CR, PR, SD) in months
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have histologically or cytologically confirmed diagnosis of locally advanced metastatic melanoma or cutaneous squamous cell carcinoma that has failed standard therapies
-
For patients treated intratumorally, must have a lesion suitable for direct injection of MG1-MAGEA3
-
Have at least one tumor amenable to biopsy
-
Have measurable disease via RECIST 1.1 criteria
-
Adequate organ function and performance status
-
Additional inclusion criteria present
Exclusion Criteria:
-
Prior treatment with any MAGE-A3 vaccine immunotherapy
-
Prior systemic therapy for cancer within 4 weeks (8 weeks for lung radiation), and has recovered from chemo-related toxicities to Grade 1 or less
-
Intolerant to prior PD1/PD-L1 therapy
-
Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections.
-
Known active CNS metastases and/or carcinomatous meningitis.
-
Active autoimmune disease that has required systemic therapy in the past 2 years.
-
Conditions likely to have resulted in splenic dysfunction.
-
Known HIV/AIDS, active HBV or HCV infection.
-
Additional Exclusion criteria exist
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Turnstone Biologics, Corp.
Investigators
- Study Director: Steve Bernstein, MD, Turnstone Biologics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Ad/MG1-MAGEA3-003